Neuronal α-Synuclein Disease Stage Progression over 5 Years.

Tanya Simuni¹, Caroline Gochanour², Anuprita R Nair², Michael C Brumm², Christopher Coffey², Kathleen L Poston³, Lana M Chahine⁴, Daniel Weintraub⁵, Caroline M Tanner⁶, Paulina Gonzalez-Latapi¹, Catherine M Kopil⁷, Yuge Xiao⁷, Sohini Chowdhury⁷, Tien Dam⁸, Gennaro Pagano⁹, Diane Stephenson¹⁰, Andrew Siderowf¹¹, Billy Dunn⁷, Kenneth Marek¹²,

¹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

²Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.

³Department of Neurology, Stanford University School of Medicine, Palo Alto, California, USA.

⁴Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

⁵Department of Psychiatry, University of Pennsylvania and the Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, USA.

⁶Department of Neurology, Movement Disorders and Neuromodulation Center, Weill Institute for Neuroscience, University of California, San Francisco, California, USA.

⁷The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.

⁸Neumora, Boston, Massachusetts, USA.

⁹F. Hoffmann-La Roche Ltd., Basel, Switzerland.

¹⁰Critical Path for Parkinson's, Critical Path Institute, Tucson, Arizona, USA.

¹¹Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

¹²Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Neuronal α-synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha-synuclein (n-asyn) pathology. The NSD integrated staging system (NSD-ISS) for research describes progression across the disease continuum as stages 0 to 6. OBJECTIVE: The aim was to assess 5-year longitudinal change in NSD-ISS in early disease. METHODS: Analysis included a subset o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.